Strikingly, the combined targeting of CDK4/6 and HER2 using abemaciclib and trastuzumab in patient-derived xenograft (PDX) models of treatment-refractory HER2-positive breast cancer displayed enhanced anti-tumor activity in vivo. This evidence concerns the gene ERBB2 and breast carcinoma.